Faricimab yields fast real-world fluid reduction in diabetic macular edema

DENVER —The largest global, prospective, noninterventional study of faricimab demonstrated “robust, rapid” anatomical improvements in patients with diabetic macular edema, according to a speaker. The VOYAGER study included real-world data from more than 5,000 patients from 28 countries who were treated with Vabysmo (faricimab, Genentech/Roche) for DME, wet age-related macular degeneration or

Raccontata dahealio.com